We would like to understand the relationship between drug launch / supply of new drugs and the broader commercial environment, including price regulation and other cost control measures.

Background

The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country.

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • But does it work? Exploring the techno-scientific and socio-political dynamics of Health Technology Assessment and Pharmaceutical Regulation

    Appropriate use of medicines can make an important contribution to public health. Yet pharmaceutical drugs are expensive and costs are increasing at a time when national health care spending is constrained. Consequently,...

    Funded by: ESRC

    Lead research organisation: King's College London

    Why might this be relevant?

    The project explores the relationship between drug launch, price regulation, and cost control measures in the context of health technology assessment and pharmaceutical regulation.

  • BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TOENHANCE THE REPURPOSING OF MEDICINES FOR ALL -REMEDI4ALL

    REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate a...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: UNIVERSITY OF HULL

    Why might this be relevant?

    The project focuses on repurposing medicines and establishing a research platform, which is partially relevant to understanding the broader commercial environment in the life sciences sector.

  • PHARLYTICS

    Competition is high in the pharma and healthcare market. Creating a new innovative drug, doesn't guarantee anyone will buy the medicine. For commercial success, a pharma company must not only provide value, but the drug ...

    Funded by: Innovate UK

    Lead research organisation: ALLOT LIMITED

    Why might this be relevant?

    The project addresses the challenges faced by pharma companies in gaining approval for new drugs, which is partially relevant to understanding the broader commercial environment in the life sciences sector.

  • HEALTH INNOVATION NEXT GENERATION PAYMENT & PRICING MODELS

    The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementatio...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: THE OFFICE OF HEALTH ECONOMICS

  • Who will pay to save 10,000 lives a year? A market analysis of personalised medicine.

    Medicine is traditionally one-size-fits all, but the reality is that not everyone responds to medicines the same. While a drug is effective and well tolerated in one person, for another it won’t work or they’ll suffer fr...

    Funded by: Innovate UK

    Lead research organisation: GENEIX

  • REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

    REMEDI4ALL aims to establish Europe's leadership globally in the re-purposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate ...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: UNIVERSITY OF SHEFFIELD

  • Better measurement of the complementarity between UK public, charity and private medical research

    Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector bui...

    Funded by: MRC

    Lead research organisation: King's College London

  • FUTURE TARGETED HEALTHCARE MANUFACTURING HUB

    By 2025 targeted biological medicines, personalised and stratified, will transform the precision of healthcare prescription, improve patient care and quality of life. Novel manufacturing solutions have to be created if t...

    Funded by: EPSRC

    Lead research organisation: University College London

  • Bioprocessing Network: BioProNET

    Biologics are complex molecules made by cellular processes and such biological products have major economic and social value for the UK and globally. Biologics encompass a range of molecules of therapeutic (e.g. biopharm...

    Funded by: BBSRC

    Lead research organisation: University of Kent

  • Stratified Medicine Business Platform

    Janssen UCL Medicinal Personalization “JUMP” TSB-SM 1101 CRD MED DBM 60171/101020 Stratified medicine opens up opportunities to significantly improve treatment outcomes in patient care while at the same time providing im...

    Funded by: Innovate UK

    Lead research organisation: JANSSEN-CILAG LIMITED

Similar ARIs from other organisations